Keywords: عامل ضد ویروسی مستقیم عمل; AIDS; acquired immunodeficiency syndrome; ALT; alanine aminotransferase; ANRS; French Research Agency on HIV/AIDS and viral hepatitis; ART; antiretroviral treatment; AST; aspartate aminotransferase; DAA; direct-acting antiviral agent; GAVI; Global Allianc
مقالات ISI عامل ضد ویروسی مستقیم عمل (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: عامل ضد ویروسی مستقیم عمل; DAA; NS3/4A Protease Inhibitor; Nucleoside/Nucleotide; Non-nucleoside; DAA; direct-acting antiviral agent; DCV; daclatasvir; HCV; hepatitis C virus; HTA; host-targeted antiviral agent; IFN; interferon; ISG; interferon-stimulated gene; NI; nucleoside inhib
Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis
Keywords: عامل ضد ویروسی مستقیم عمل; Direct-Acting Antiviral Agent; Outcome; Drug Resistance; AE; adverse event; HCV; hepatitis C virus; HIV; human immunodeficiency virus; NS5A; nonstructural protein 5A; NS5B; nonstructural protein 5B; RAS; resistance-associated substitution; SAE; serious ad
Discovery of BMS-961955, an allosteric inhibitor of the hepatitis C virus NS5B polymerase
Keywords: عامل ضد ویروسی مستقیم عمل; HCV NS5B; Polymerase; Cyclopropyl-fused indolobenzazepine; Metabolic stability; Direct-acting antiviral agent; Antiviral agent;
Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials
Keywords: عامل ضد ویروسی مستقیم عمل; Direct-Acting Antiviral Agent; Shortened Duration Therapy; Clinical Trial; Comparison; CI; confidence interval; DAA; direct-acting antiviral agent; HCV; hepatitis C virus; SVR; sustained virologic response;
Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation
Keywords: عامل ضد ویروسی مستقیم عمل; Population Analysis; US; DAA Therapy; Obesity; ALD; alcohol-related liver disease; CI; confidence interval; CTP; Child-Turcotte-Pugh; CLF; chronic liver failure; DAA; direct-acting antiviral agent; HCC; hepatocellular carcinoma; HCV; hepatitis C virus; HI
Hepatitis due to Reactivation of Hepatitis B Virus in Endemic Areas Among Patients With Hepatitis C Treated With Direct-acting Antiviral Agents
Keywords: عامل ضد ویروسی مستقیم عمل; Therapy; Risk Factor; Coinfection; Prognostic Factor; CHC; chronic hepatitis C; DAA; direct-acting antiviral agent; HBeAg; hepatitis B e antigen; HBsAg; hepatitis B surface antigen; HBV; hepatitis B virus; HCC; hepatocellular carcinoma; HCV; hepatitis C v
Real-World Effectiveness and Safety of Oral Combination Antiviral Therapy for Hepatitis C Virus Genotype 4 Infection
Keywords: عامل ضد ویروسی مستقیم عمل; Routine Clinical Practice; Direct-Acting Antiviral Agents; Cirrhosis; Genotype 4; DAA; direct-acting antiviral agent; EOT; end of treatment; GT; genotype; HCV; hepatitis C virus; LDV; ledipasvir; OMV; ombitasvir; PTV; paritaprevir; r; ritonavir; RBV; riba
Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C
Keywords: عامل ضد ویروسی مستقیم عمل; Direct-acting antiviral agent; Hepatocarcinogenesis; Wisteria floribunda agglutinin positive Mac-2 binding protein; HCC occurrence; HCC recurrence;
Daclatasvir Prevents Hepatitis C Virus Infectivity by Blocking Transfer of the Viral Genome to Assembly Sites
Keywords: عامل ضد ویروسی مستقیم عمل; Chronic Hepatitis C; Direct-Acting Antiviral Agent; DAA; CHX; cycloheximide; DCV; daclatasvir; DI; domain I; DMV; double membrane vesicle; ER; endoplasmic reticulum; HCV; hepatitis C virus; LD; lipid droplet; MOI; multiplicity of infection; NS; non-struct
ReviewThe importance of resistance to direct antiviral drugs in HCV infection in clinical practice
Keywords: عامل ضد ویروسی مستقیم عمل; HCV; hepatitis C virus; DAA; direct-acting antiviral agent; NS3; non-structural protein 3; NS5A; non-structural protein 5A; NS5B; non-structural protein 5B; RAVs; resistance associated variants; IP-10; interferon-gamma-inducible protein 10; IFNL4; interfe
Efficacy of the Combination of Sofosbuvir, Velpatasvir, and the NS3/4A Protease Inhibitor GS-9857 in Treatment-Naïve or Previously Treated Patients With Hepatitis C Virus Genotype 1 or 3 Infections
Keywords: عامل ضد ویروسی مستقیم عمل; Clinical Trial; LEPTON; Difficult to Treat; Time of Treatment; DAA; direct-acting antiviral agent; HCV; hepatitis C virus; PEG+RBV; pegylated interferon plus ribavirin; RAS; resistance-associated substitution; SOF; sofosbuvir; SVR12; sustained virologic r
Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Hepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Open-Label, Phase 2 Trial
Keywords: عامل ضد ویروسی مستقیم عمل; Clinical Trial; Direct-Acting Antiviral; DAA; Non-Genotype 1 HCV; CI; confidence interval; DAA; direct-acting antiviral agent; HCV; hepatitis C virus; RAS; resistance-associated substitution; SVR; sustained virologic response; SVR12; sustained virologic r
Case ReportRapid clearance of HCV-related splenic marginal zone lymphoma under an interferon-free, NS3/NS4A inhibitor-based treatment. A case report
Keywords: عامل ضد ویروسی مستقیم عمل; HCV; hepatitis C virus; NHL; non-Hodgkin lymphoma; SMZL; splenic marginal zone lymphoma; NS3; non-structural protein 3; IFN; interferon; RBV; ribavirin; FDV; faldaprevir; DLV; deleobuvir; DAA; direct-acting antiviral agent; MALT; mucosa-associated lymphoi
Serious Pulmonary Toxicity Secondary to Novel Hepatitis C Antiviral Therapy in a Liver Transplant Recipient
Keywords: عامل ضد ویروسی مستقیم عمل; DAA; direct-acting antiviral agent; DAD; diffuse alveolar damage; FDA; Food and Drug Administration; HCV; hepatitis C virus; LT; liver transplant; SIM; simeprevir; SOF; sofosbuvir;
Research ArticleHepatitis C virus variants resistant to macrocyclic NS3-4A inhibitors subvert IFN-β induction by efficient MAVS cleavage
Keywords: عامل ضد ویروسی مستقیم عمل; CHC; chronic hepatitis C; DAA; direct-acting antiviral agent; HCV; hepatitis C virus; IFN; interferon; IP-10; interferon-γ-induced protein 10; MAVS; mitochondrial antiviral-signaling protein; MD; molecular dynamics; PI; protease inhibitor; RAV; resistanc
Research ArticleVirology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies
Keywords: عامل ضد ویروسی مستقیم عمل; HCV; hepatitis C virus; PR; peginterferon and ribavirin; QD; once-daily; GT; genotype; SVR; sustained virologic response; DAA; direct-acting antiviral agent; EC50; half maximal effective concentration; EOS; end of study; Hepatitis C virus; Genotype 1; Onc
Research ArticlePharmacokinetics and safety of co-administered paritaprevir plus ritonavir, ombitasvir, and dasabuvir in hepatic impairment
Keywords: عامل ضد ویروسی مستقیم عمل; HCV; hepatitis C virus; Cmax; maximal plasma concentration; AUC; area under the plasma concentration-time curve; DAA; direct-acting antiviral agent; NS; nonstructural; CYP; cytochrome P450; Paritaprevir/r; paritaprevir administered with ritonavir; SVR12;
Research ArticleDrug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir
Keywords: عامل ضد ویروسی مستقیم عمل; PTV/r; paritaprevir/ritonavir; OBV; ombitasvir; DSV; dasabuvir; DAA; direct-acting antiviral agent; HCV; hepatitis C virus; Cmax; maximum observed plasma concentration; AUC; area under the plasma concentration-time curve; SVR; sustained virologic response
Alisporivir Inhibition of Hepatocyte Cyclophilins Reduces HBV Replication and Hepatitis B Surface Antigen Production
Keywords: عامل ضد ویروسی مستقیم عمل; Cyclophilin Inhibition; Direct-Acting Antiviral Agent; Peptidyl-Prolyl Isomerase; Viral Replication; ALV; alisporivir; BL; baseline; CYP; cyclophilin; DMEM; Dulbecco's modified Eagle medium; DMSO; dimethyl sulfoxide; ELISA; enzyme-linked immunosorbent a
Journal of Hepatology Update: Hepatitis CSimplification of antiviral hepatitis C virus therapy to support expanded access in resource-limited settings
Keywords: عامل ضد ویروسی مستقیم عمل; ARV; antiretroviral; ART; antiretroviral therapy; DAA; direct-acting antiviral agent; FDC; fixed-dose combination; HCV; hepatitis C virus; HIV; human immunodeficiency virus; IFN; interferon; PCR; polymerase chain reaction; RBV; ribavirin; WHO; World Healt
Original ResearchFull Report: Clinical-LiverABT-450, Ritonavir, Ombitasvir, and Dasabuvir Achieves 97% and 100% Sustained Virologic Response With or Without Ribavirin in Treatment-Experienced Patients With HCV Genotype 1b Infection
Keywords: عامل ضد ویروسی مستقیم عمل; PEARL-II; Ribavirin-Free; IFN; Interferon-Free Therapy; AE; adverse event; ALT; alanine aminotransferase; AST; aspartate aminotransferase; CI; confidence interval; DAA; direct-acting antiviral agent; HCV; hepatitis C virus; pegIFN; peginterferon; RBV; rib
Research ArticleA randomized, double-blind, multiple-dose study of the pan-genotypic NS5A inhibitor samatasvir in patients infected with hepatitis C virus genotype 1, 2, 3 or 4
Keywords: عامل ضد ویروسی مستقیم عمل; HCV; hepatitis C virus; NS5A; nonstructural protein 5A; DAA; direct-acting antiviral agent; EC50; 50% effective concentration; CYP; cytochrome P450; HBV; hepatitis B virus; HIV; human immunodeficiency virus; QD; once daily; BID; twice daily; AE; adverse e
Simeprevir With Peginterferon and Ribavirin Leads to High Rates of SVR in Patients With HCV Genotype 1 Who Relapsed After Previous Therapy: A Phase 3 Trial
Keywords: عامل ضد ویروسی مستقیم عمل; PROMISE; Chronic Hepatitis C; Drug; DAA; AE; adverse event; CI; confidence interval; DAA; direct-acting antiviral agent; EC50; median effective concentration; EOT; end of treatment; FDA; Food and Drug Administration; HCV; hepatitis C virus; IQR; interquar
Combination of Vaniprevir With Peginterferon and Ribavirin Significantly Increases the Rate of SVR in Treatment-Experienced Patients With Chronic HCV Genotype 1 Infection and Cirrhosis
Keywords: عامل ضد ویروسی مستقیم عمل; Clinical Trial; Fibrosis; Direct-Acting Antiviral Agent; HCV; hepatitis C virus; LLQ; lower limit of quantification; mITT; modified intention-to-treat; P/R; peginterferon alfa and ribavirin; RAV; resistance-associated variants; RVR; rapid virologic respon
Original ResearchFull Report: Basic and Translational-LiverA Serine Palmitoyltransferase Inhibitor Blocks Hepatitis C Virus Replication in Human Hepatocytes
Keywords: عامل ضد ویروسی مستقیم عمل; Direct-Acting Antiviral Agents; DAAs; HCV Lifecycle; Drug; cDNA; complementary DNA; DAA; direct-acting antiviral agent; HCV; hepatitis C virus; IC50; 50% inhibitory concentration; PCR; polymerase chain reaction; PEG-IFN; pegylated interferon alfa-2a; RBV;
Genetic Factors and Hepatitis C Virus Infection
Keywords: عامل ضد ویروسی مستقیم عمل; DAA; direct-acting antiviral agent; HCV; hepatitis C virus; ISG; interferon-stimulated genes; ITPase; inosine triphosphatase; pegIFN; peginterferon alfa; RBV; ribavirin; SNP; single nucleotide polymorphisms; SVR; sustained virological response;
PharmacotherapyNew drug reviewBoceprevir: A Protease Inhibitor for the Treatment of Hepatitis C
Keywords: عامل ضد ویروسی مستقیم عمل; boceprevir; direct-acting antiviral agent; nonstructural protein 3 serine protease inhibitor; SCH 503034;